Primary Outcome Measures
- Successful remission rate: [ Time Frame: 3 months ]
successful remission is defined as absence of intraepithelial neoplasia in biopsies of original locations at 3 months after HybridAPC upon follow up
Secondary Outcome Measures
- Complications [ Time Frame: 3 months ]
possible complications include perforation, bleeding, fever, stenosis, cough and etc.
Eligibility Criteria
- Inclusion Criteria
- Bronchoscopy and fluorescence bronchoscopy found endoluminal growth lesions of upper segmental bronchus. AFB indicates malignant possibility.
- Size ≤ 20 mm
- Flat, nodule or polypoid type
- Negative imaging: HRCT indicates no tumor in lung and lymph node enlargement; or PET-CT finds no lesions in lung or suspicious lymph node tumors involve.
- Clinical stage: Tis or T1N0M0
- High-grade intraepithelial neoplasia (including severe atypical dysplasia and carcinoma in situ) or squamous cancer confirmed by biopsy histopathology
- High-frequency EBUS indicates the depth of lesions is cartilage endomembrane or internal part of adventitia of tracheal membranous part
- Patients are not suitable for surgery or refuse surgery
- Inform consent is available
- Exclusion Criteria
- Patients with severe cardiopulmonary dysfunction or other contraindication can not tolerate endoscopic examination and treatment
- Severe bleeding tendency
- Poor compliance
- Unstable vital signs
- Investigators consider subjects should not be included because of specific situations
